ArticleBlood2011
How I treat essential thrombocythemia.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 113 citations in OpenAlex.
- A Case of acute Myocardial Infarction in a Patient with Essential Thrombocythaemia Treated with Anagrelide.European journal of case reports in internal medicine · 2024Article
- Prodrug approaches for the development of a long-acting drug delivery systems.Advanced drug delivery reviews · 2023Review
- Megakaryocyte Diversity in Ontogeny, Functions and Cell-Cell Interactions.Frontiers in oncology · 2022Article
- Cardiac Surgery Using Hypothermic Circulatory Arrest in a Case of Essential Thrombocythemia.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020Article
- Triple-Negative Essential Thrombocythemia Complicated by Thrombosis and Acquired von Willebrand Disease in a Young Man.The American journal of case reports · 2020Article
- Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Analysis of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and mean platelet volume to platelet count ratio in children with acute stage of immunoglobulin A vasculitis and assessment of their suitability for predicting the course of the disease.Rheumatology international · 2019Article
- Platelet count abnormalities and peri-operative outcomes in adults undergoing elective, non-cardiac surgery.PloS one · 2019Article
- The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis.Journal of thrombosis and thrombolysis · 2018Article
- Coexistent Breast Cancer and Essential Thrombocythemia: How We Addressed the Therapeutic Challenges.Case reports in hematology · 2018Article
- Myeloproliferative neoplasms: from origins to outcomes.Hematology. American Society of Hematology. Education Program · 2017Review
- Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review.Journal of thrombosis and thrombolysis · 2017Review
- Genomic profile of a patient with triple negative essential thrombocythemia, unresponsive to therapy: A case report and literature review.Journal of advanced research · 2017Article
- Equivalence of BCSH and WHO diagnostic criteria for ET.Leukemia · 2017Article
- Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Haematologica · 2017Review
- [Chinese expert consensus on the diagnosis and treatment of essential thrombcythaemia(2016)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.Stem cell investigation · 2016Article
- Thrombotic risk assessment in 185 WHO-defined essential thrombocythemia patients: single center experience.Contemporary oncology (Poznan, Poland) · 2015Article
- MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.Mediators of inflammation · 2015Review
- JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.Blood · 2014Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
In the past 5 years we have witnessed significant advances in both the diagnostic process and optimal therapy for patients with essential thrombocythemia (ET). Insights into the underlying molecular mechanisms have been accompanied by the development of new diagnostic tests and by an improved understanding of the relationship between ET and other related myeloproliferative neoplasms, such as polycythemia vera and primary myelofibrosis. In the first part of this review, we describe how recent molecular and histologic studies can be integrated into a streamlined diagnostic process that is applicable to everyday clinical practice. We also address areas of current diagnostic controversy, including heterogeneity within ET and the phenotypic overlap between ET, polycythemia vera, and primary myelofibrosis. In the second part, we provide an overview of our current approach to the treatment of ET, including risk stratification, choice of cytoreductive agent, and a consideration of special situations such as the pregnant or perioperative patient. Areas of controversy discussed include the identification of those at high risk of complications and therapeutic decisions in the younger patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.